Dystonia and parkinsonism

Parkinsonism and Related Disorders

Volumn 8, Issue 2, 2001, Pages 109-121

  Jankovic, Joseph ^a   Tintner, Ron ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

BASAL GANGLION; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DYSTONIA; FEMALE; GENETIC DISORDER; GLOBUS PALLIDUS; HUMAN; METABOLIC DISORDER; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SUBTHALAMIC NUCLEUS; THALAMUS; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; DYSTONIA; HUMANS; LEVODOPA; PARKINSONIAN DISORDERS; SYNDROME;

EID: 0034905695     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(01)00025-6     Document Type: Conference Paper

References (140)

1. Classification of dystonia
2. Lessons from a remarkable family with dopa-responsive dystonia
3. Dystonia in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy
4. Forms of dystonia in patients with Parkinson's disease
5. Secondary dystonia
6. Parkinsonism and dystonia, pseudoparkinsonism and pseudodystonia
7. Dystonia and Parkinson's disease
8. A family with hereditary juvenile dystonia-parkinsonism
9. Young-onset Parkinson's disease: A clinical pathologic description of two siblings
10. Dystonia-Parkinson syndrome: Differential effects of levodopa and dopamine agonists
11. Dystonia in untreated parkinsonism
12. Dystonia in Parkinson's disease: Clinical and pharmacological features
13. Paralysis agitans with an account of a new symptom
14. Practical management of dystonia
15. The response to muscle stretch and shortening in Parkinsonian rigidity
16. Foot dystonia and lumbar canal stenosis
17. Management of focal dystonia of the extensor hallucis longus muscle with botulinum toxin injection: A case report
18. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome
19. The nature of apraxia
20. Influence of dystonia on the response to long-term L-dopa therapy in Parkinson's disease
21. Idiopathic blepharospasm does not lead to a parkinsonian syndrome: Results of a questionnaire-based follow-up study
22. 'Apraxia of lid opening.' A focal eyelid dystonia: Clinical study of 32 patients
23. A new variant of blepharospasm
24. Meige syndrome in the spectrum of Lewy body disease
25. Hemiparkinsonism and hemiatrophy
26. Hemiparkinsonism as a late complication of hemiatrophy: A new syndrome
27. Parkinsonism, dystonia and hemiatrophy
28. Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: A dystonic phenomenon?
29. Camptocormia (bent spine) in patients with Parkinson's disease - Characterization and possible pathogenesis of an unusual phenomenon
30. Isolated neck extensor myopathy: A common cause of dropped head syndrome
31. Dropped head syndrome and bent spine syndrome: Two separate clinical entities or different manifestations of axial myopathy
32. Hand contractures in Parkinson's disease
33. Dystonic foot response of Parkinsonism
34. Parkinsonism following dystonia in three patients
35. Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot?
36. The spectrum of levodopa-induced dyskinesias
37. Levodopa-induced dyskinesias in Parkinson's disease: Phenomonology and pathophysiology
38. End-of-dose dystonia in Parkinson's disease
39. Early morning dystonia in Parkinson's disease
40. Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease
41. Complex dystonia of Parkinson's disease: Clinical features and relation to plasma levodopa profile
42. Continuous levodopa infusions to treat complex dystonia in Parkinson's disease
43. Severe evening dyskinesias in advanced Parkinson's disease: Clinical description, relation to plasma levodopa, and treatment
44. Diagnostic criteria for Parkinson disease
45. Contracture of extremities in Parkinsonian subjects: A report of three cases with a possible association with bromcoriptine treatment
46. Limb contractures in levodopa-responsive parkinsonism: A clinical and investigational study of seven new cases
47. Progressive supranuclear palsy
48. The clinical and pathological spectrum of Steele-Richardson-Olszweski syndrome (progressive supranuclear palsy): A reappraisal
49. Dystonia in progressive supranuclear palsy
50. Limb dystonia in progressive supranuclear palsy
51. An extended 5′-tau susceptibility haplotype in progressive supranuclear palsy
52. Paraneoplastic degeneration of the substantia nigra with dystonia and parkinsonism
53. Multiple system atrophy
54. Multiple system atrophy: A review of 203 pathologically proven cases
55. Corticodentatonigral degeneration with neuronal achromasia
56. Dystonia in corticobasal degeneration
57. Dystonia caused by toxins
58. Hereditary progressive dystonia with marked duiurnal variation
59. Dopa-responsive dystonia: The spectrum of clinical manifestations in a large North American family
60. Dopa-responsive dystonia is induced by a dominant-negative mechanism
61. Molecular mechanisms of hereditary progressive dystonia with marked diurnal fluctuation, Segawa's disease
62. L-Dopa-responsive infantile hypokinetic rigid parkinsonism due to tyrosine hydroxylase deficiency
63. Rapid-onset dystonia-parkinsonism: Linkage to chromosome 19q13
64. Dopa-responsive dystonia: Recent advances and remaining issues to be addressed
65. Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism
66. Variable phenotype of rapid-onset dystonia-parkinsonism
67. Refined linkage disequilibrium and physical mapping of the gene locus for X-linked dystonia-parkinsonism (DYT3)
68. The phenotype of the X-linked dystonia-parkinsonism syndrome. An assessment of 42 cases in the Philippines
69. Positron emission tomographic findings in Filipino X-linked dystonia-parkinsonism
70. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
71. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe
72. Association between early-onset Parkinson's disease and mutations in the parkin gene
73. Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations?
74. CAG expansions in a novel gene for Machado-Joseph disease at chromsome 14q32.1
75. Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: Confirmation of 14q CAG expansion
76. Machado-Joseph disease presenting as severe generalised dystonia in a German patient
77. Decreased dopamine transporter binding in Machado-Joseph disease
78. Recent advances on the pathogenesis of Huntington's disease
79. Bradykinesia in early Huntington's disease
80. Bradykinesia in Huntington's disease
81. Late onset levodopa responsive Huntington's disease withminimal chorea masquerading as Parkinson plus syndrome
82. Atypical movement disorders in the early stages of Huntington's disease: Clinical and genetic analysis
83. Cervical dystonia as the initial presentation of Huntington's disease
84. Dystonia in Huntington's disease: Prevalence and clinical characteristics
85. Dystonia-predominant adult-onset Huntington disease: Association between motor phenotype and age of onset in adults
86. Disorders of copper transport
87. Wilson's disease: Clinical analysis of 71 cases and comparison with previous Chinese series
88. Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging
89. Wilson's disease: MRI with clinical correlation
90. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease
91. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13
92. The nosology of Hallervorden-spatz disease
93. Late onset Hallervorden-Spatz disease presenting as familial parkinsonism
94. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis - A new syndrome
95. Neuroacanthocytosis presenting as parkinsonism
96. Parkinsonism with neuroacanthocytosis
97. Essential tremor and other disorders
98. Idiopathic cervical dystonia: Clinical characteristics
99. Cervical dystonia: Clinical findings and associated movement disorders
100. Hand tremor in patients with spasmodic torticollis
101. The relationship of essential tremor to other movement disorders: Report on 678 patients
102. Essential tremor: Clinical characteristics
103. Familial essential tremor in 4 kindreds. Prospects for genetic mapping
104. A gene (ETM) for essential tremor maps to chromosome 2p22-p25
105. Evidence that a gene for essential tremor maps to chromosome 2p in four families
106. The pathophysiology of primary dystonia
107. The anatomical basis of symptomatic hemidystonia
108. Hemidystonia: A report of 22 patients and a review of the literature
109. The behavioral and motor consequences of focal lesions of the basal ganglia in man
110. Movement disorders following lesions of the thalamus
111. Symptomatic dystonias associated with structural brain lesions: Report of 16 cases
112. Post mortem studies in Parkinson's disease - Is it possible to detect brain areas for specific symptoms?
113. Parkinsonian akinesia, rigidity and tremor in the monkey. Histopathological and neuropharmacological study
114. The pharmacology of foot dystonia in parkinsonism
115. Treatment of dystonia occurring in parkinsonian syndromes by botulinum toxin
116. 'Off' painful dystonia in Parkinson's disease treated with botulinum toxin
117. Operative management of foot and ankle equinovarus associated with focal dystonia
118. Severe constipation in Parkinson's disease relieved by botulinum toxin
119. Adductor laryngeal breathing dystonia in a patient with lubag (X-linked dystonia-parkinsonism syndrome)
120. Toxin for the so-called apraxia of lid opening
121. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: Report of two cases
122. Botulinum toxin injections to one leg alleviate freezing of gait in a patient with Parkinson's disease
123. AACPDM Treatment Outcomes Committee Review Panel. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy
124. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy
125. Intrathecal baclofen for dystonia: Benefits and complications during six years of experience
126. Surgery for Parkinson disease. A critical evaluation of the state of the art
127. Surgery for levodopa-induced dyskinesias
128. Pallidotomy for generalized dystonia
129. Long-term efficacy of, posteroventral pallidotomy in the treament of Parkinson's disease
130. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced parkinson disease
131. Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus
132. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity
133. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballism
134. Pathophysiology of the basal ganglia in Parkinson's disease
135. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications
136. Evolution of diagnosis in early Parkinson's disease